FDA Accepts Merck New Drug Application for Sugammadex Sodium Injection

Merck’s new drug application resubmission for sugammadex sodium injection has been accepted for review by the FDA.

Advertisement

Neuromuscular blockade, which is used by anesthesiologists to relax muscles during surgery, is revered by the sugammadex sodium injection. Upon approval, this substance would be one of the first medicines of its kind to be used in the U.S. surgical setting.

The FDA previously rejected the NDA in 2008 and requested more data on allergic reactions and bleeding events. The application has now been deemed complete for review.

More Articles on Anesthesia:

Novitas Expected to Revise Limits to Anesthesia Coverage
6 ASC Characteristics That Matter to Anesthesiologists
Children’s National Medical Center Names Joint Chief Medical Officers

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Anesthesia

  • As the shortage of physician anesthesiologists across the U.S. becomes more severe, certified-registered nurse anesthetists have emerged as an essential…

  • As of April 6, 2026, CRNAs’ average annual salary is $276,434, according to salary transparency platform Marit Health’s compilation of…

Advertisement

Comments are closed.